Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline), a novel, fully synthetic, fluorocycline intravenous antibiotic, in China.
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 18, 2023
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Details : The license agreement is focused on ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
June 08, 2020